menu
    • menu
    [{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"Statera Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Entolimod","moa":"TLR5","graph1":"Oncology","graph2":"Preclinical","graph3":"Coeptis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Coeptis Therapeutics \/ Coeptis Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Coeptis Therapeutics \/ Coeptis Therapeutics"},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"Bull Horn Holdings Corp.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Merger","leadProduct":"Anti-CD38 Monoclonal Antibody","moa":"CD38","graph1":"Oncology","graph2":"Preclinical","graph3":"Coeptis Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Coeptis Therapeutics \/ Bull Horn Holdings Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Coeptis Therapeutics \/ Bull Horn Holdings Corp."},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"University of Pittsburgh","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"CAR-T Cell Therapy","moa":"mSA2 affinity-enhanced biotin","graph1":"Oncology","graph2":"Preclinical","graph3":"Coeptis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Coeptis Therapeutics \/ University of Pittsburgh","highestDevelopmentStatusID":"4","companyTruncated":"Coeptis Therapeutics \/ University of Pittsburgh"},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"The University of Pittsburgh School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"SNAP-CAR T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Coeptis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Coeptis Therapeutics \/ University of Pittsburgh","highestDevelopmentStatusID":"4","companyTruncated":"Coeptis Therapeutics \/ University of Pittsburgh"},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"IQVIA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"SNAP CAR T-cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Coeptis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Coeptis Therapeutics \/ IQVIA","highestDevelopmentStatusID":"4","companyTruncated":"Coeptis Therapeutics \/ IQVIA"},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"Deverra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"DVX201","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Coeptis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coeptis Therapeutics \/ Coeptis Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Coeptis Therapeutics \/ Coeptis Therapeutics"},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"DVX201","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Coeptis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Coeptis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Coeptis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Coeptis Therapeutics","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"SNAP CAR T-cell","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Coeptis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Coeptis Therapeutics \/ Coeptis Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Coeptis Therapeutics \/ Coeptis Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Coeptis Therapeutics

    Menu

    Coeptis Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Coeptis Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Coeptis Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNAP CAR T-cell

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : University of Pittsburgh

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Techn...

                            Details : Companies are expanding this agreement to include engineering of NK cells to generate SNAP-CAR NK therapies, to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including HER2-expressing cancer.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 11, 2023

                            Lead Product(s) : SNAP CAR T-cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : University of Pittsburgh

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Coeptis Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Coeptis Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DVX201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Re...

                            Details : DVX201 is a novel allogeneic, unmodified natural killer (NK) cell therapy, which is investigated for the treatment of relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) and patients hospitalized with COVID-19 inf...

                            Brand Name : DVX201

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 14, 2023

                            Lead Product(s) : DVX201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Coeptis Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Coeptis Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DVX201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Deverra Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Tri...

                            Details : Coeptis will get exclusive rights to two FDA approved IND applications and two phase 1 clinical trials investigating infusion of DVX201, an unmodified natural killer (NK) cell therapy generated from pooled donor CD34+ cells, in hematologic malignancies a...

                            Brand Name : DVX201

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 18, 2023

                            Lead Product(s) : DVX201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Deverra Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Coeptis Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Coeptis Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNAP CAR T-cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : IQVIA

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program

                            Details : Under the terms of the agreement, IQVIA will collaborate with Coeptis to prioritize the target indications for the SNAP-CAR program and manage activities designed to enable the filing of an Investigational New Drug (IND) application.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 22, 2022

                            Lead Product(s) : SNAP CAR T-cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : IQVIA

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Coeptis Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Coeptis Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNAP-CAR T Cell Therapy,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : The University of Pittsburgh School of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, ...

                            Details : Current SNAP-CAR T therapies are designed to target specific tumor antigens that correspond to a specific cancer indication. This approach has proven effective in certain cancer types but limits the applicability of those CAR T therapies.

                            Brand Name : SNAP-CAR T Cell Therapy

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 21, 2022

                            Lead Product(s) : SNAP-CAR T Cell Therapy,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : The University of Pittsburgh School of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Coeptis Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Coeptis Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : University of Pittsburgh

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T ...

                            Details : The option agreement involves the intellectual property rights to three technologies jointly 1) mSA2 affinity-enhanced biotin-binding CAR, 2) universal self-labeling SynNotch and CARs for programable antigen-targeting, and 3) conditional control of unive...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 17, 2022

                            Lead Product(s) : CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : University of Pittsburgh

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Coeptis Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Coeptis Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CD38-GEAR-NK,Anti-CD38 Monoclonal Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Bull Horn Holdings Corp.

                            Deal Size : $175.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement

                            Details : CD38-Diagnostic is a pre-clinical in vitro screening tool to potentially pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 mAb therapies, either as a monotherapy or in combination with CD38-GEAR-NK.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 19, 2022

                            Lead Product(s) : CD38-GEAR-NK,Anti-CD38 Monoclonal Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Bull Horn Holdings Corp.

                            Deal Size : $175.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Coeptis Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Coeptis Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Entolimod

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Statera Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod

                            Details : Under the terms of the definitive agreement, Statera will receive upfront payment and revenue-based milestone payments from Coeptis in exchange for Statera’s rights to any product containing Entolimod as an active ingredient and all other related TLR5 ...

                            Brand Name : CBLB502

                            Molecule Type : Large molecule

                            Upfront Cash : $6.0 million

                            April 13, 2022

                            Lead Product(s) : Entolimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Statera Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth